Patents by Inventor David Spaner

David Spaner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050063995
    Abstract: Disclosed are novel compositions, methods and vaccines, which upon administration to a patient suffering from a melanoma, colon carcinoma tumor or breast cancer, postpone and/or reduce the need for chemotherapy treatment, slow the progression of or eliminate the tumor and/or alleviate the symptoms of the tumor. The compositions comprise stressed colon carcinoma, melanoma or breast cancer cells, preferably autologous such cells.
    Type: Application
    Filed: October 25, 2001
    Publication date: March 24, 2005
    Inventors: David Spaner, Arkady Mandel
  • Publication number: 20050054665
    Abstract: The present invention provides methods for increasing expression of cell surface molecules of CD5+ B cell lymphoma cells by contacting cells with immune response modifiers. The invention also provides methods for the treatment of CD5+ B cell lymphomas, including chronic lymphocytic leukemia and small lymphocytic lymphoma, by administering immune response modifier compounds to a subject in need of such treatment. Suitable immune response modifier compounds include agonists of TLR7 and/or TLR8.
    Type: Application
    Filed: September 3, 2004
    Publication date: March 10, 2005
    Inventors: Richard Miller, David Spaner
  • Publication number: 20030108536
    Abstract: The development of graft versus host disease in a mammalian patient undergoing cell transplantation therapy for treatment of a bone marrow mediated disease, is prevented or alleviated by subjecting at lest the T-cells of the allogeneic cell transplantation composition, in admixture with red blood cells of the donor, extracorporeally, to oxidative stress, in appropriate dosage amounts, such as bubbling a gaseous mixture of ozone and oxygen through a suspension of the T-cells. The process may also include irradiation of the cells with UV light, simultaneously with the application of the oxidative stress. The oxidative stress induces reduced inflammatory cytokine production and a reduced proliferative response in the T-cells.
    Type: Application
    Filed: December 27, 2002
    Publication date: June 12, 2003
    Inventor: David Spaner